Rockwell Medical Inc(NASDAQ:RMTI) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $13.390M. Analysts estimated a revenue of $12.460M. The revenues were 7.46% above the estimates. Earnings per share were $-0.1. The reported EPS was above estimates by 9.09%. Analysts had estimated an EPS of $-0.11.
Rockwell Medical Inc (RMTI) made into the market gainers list on Fridays trading session with the shares advancing 0.33% or 0.02 points. Due to strong positive momentum, the stock ended at $6.06, which is also near the day’s high of $6.1995. The stock began the session at $5.83 and the volume stood at 3,83,703 shares. The 52-week high of the shares is $10.58 and the 52 week low is $3.55. The company has a current market capitalization of $312 M and it has 5,15,27,711 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Nov 14, 2016, Kenneth L Holt (director) sold 19,725 shares at $5.29 per share price.Also, On Dec 8, 2015, Ronald D Boyd (director) sold 12,500 shares at $10.59 per share price.On Aug 14, 2015, Robert L Chioini (CEO) purchased 4,910 shares at $11.96 per share price, according to the Form-4 filing with the securities and exchange commission.
Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.